HNGE Hinge Health, Inc. Insider Trading

Insight Holdings Group, LLC (10% Owner) sells 426,171 shares for $38,446,957.43 via scheduled 10b5-1 plan at HNGE

Insight Holdings Group, LLC executed 12 separate sales totaling 426,171 shares for $38,446,957.43 on July 7–9, 2026, at prices ranging from $90.17 to $91.00—all within 1.3% of the 52-week high of $91.07. The transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. Although the non-derivative holdings were fully liquidated through these sales, the insider retains 12,212,817 shares in derivative securities across eight ownership vehicles, so the overall position remains substantial. The timing of this activity near the 52-week high, combined with HNGE's 43.2% rise over the past 30 days and 153.9% rise over 90 days, places these sales in a context of significant recent upward price momentum.

Director Gabriel Mecklenburg sold 83,334 shares at $85.05 avg on 2026-07-01 for $7.1M under pre-arranged 10b5-1 plan

Gabriel M.I. Mecklenburg, a director at Hinge Health, executed 5 separate sales totaling 83,334 shares for $7,087,529.16 on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted 2025-12-01. The sales occurred at prices ranging from $82.97 to $86.51, with a blended average of $85.05. As a scheduled transaction, this trade does not reflect discretionary timing decisions. The insider retains significant derivative holdings of 1,644,007 Class B Common Stock shares, meaning his overall position at the company remains substantial. The company reported $182.3M in quarterly revenue with $35.1M net income and 50.6% annual revenue growth, though full-year results were unprofitable—a fact warranting attention given the size and timing of this non-discretionary reduction in common stock exposure.

Insight Holdings Group sells 1,466,667 shares of HNGE across 20 transactions for $121,489,333.19 at blended avg $82.83 under 10b5-1 plan

Insight Holdings Group, LLC executed 20 separate sales totaling 1,466,667 shares for $121,489,333.19 at a blended average price of $82.83, conducted under a pre-arranged 10b5-1 trading plan and therefore scheduled rather than discretionary. The sales occurred with the stock trading near its 52-week high of $84.62, reflecting a 30-day price appreciation of +45.0% and a 90-day price appreciation of +111.3% in the period leading up to the trade. Despite the reduction in non-derivative Table I shares to zero, Insight Holdings retains 6,441,830 shares expressed through four derivative (Class B Common Stock) holdings in Table II, meaning its overall position in HNGE remains substantial. Hinge Health reported quarterly revenue of $182.3M with annual revenue growth of +50.6%, though the company carried a negative full-year net income over its most recent fiscal year.

Insight Holdings Group LLC sold 530,982 shares for $38,137,010.65 via 12 transactions on 2026-06-25 under pre-arranged 10b5-1 plan

Insight Holdings Group, LLC, a 10% owner, executed 12 separate sales totaling 530,982 shares for $38,137,010.65 on 2026-06-25 at blended average price of $71.82, eliminating its non-derivative holdings. This transaction is part of a pre-arranged 10b5-1 trading plan, making it scheduled rather than discretionary. The insider retains Class B Common Stock derivative holdings through multiple ownership vehicles. The company's most recent quarter showed revenue of $182,307,000.00 and net income of $35,128,000.00, with annual revenue growth of +50.6%, though the company was unprofitable over its most recent full fiscal year. The current stock price of $81.48 sits 3.7% below the 52-week high of $84.62, suggesting the transaction occurred at a discount to recent peak valuations.

Insight Holdings Group (10% owner) liquidates entire 142.3K-share HNGE position for $10.2M via 10b5-1 plan

Insight Holdings Group filed a Form 4 on 2026-06-24 documenting two separate sales totaling 142,311 shares at $71.67, reducing its holdings from 142.3K shares to 0 shares (a -100.0% reduction). The transaction was executed under a pre-arranged 10b5-1 trading plan, indicating scheduled execution rather than discretionary timing. While the company shows strong recent momentum—30-day change +27.7%, 90-day change +75.6%—and posted revenue of $182.3M with net income of $35.1M in the latest quarter alongside 50.6% annual revenue growth, Insight Holdings' prior trades at HNGE show a mixed pattern, including four separate sales on 2025-12-01 that experienced subsequent 90-day declines of -10.5%. The complete exit is significant given the 10% ownership stake, though the scheduled nature of the 10b5-1 plan removes timing as an interpretive variable.

Insight Holdings Group, LLC sells 727,793 shares of HNGE for $51,634,252.32 under 10b5-1 plan; retains 26,497,370 derivative shares.

Insight Holdings Group, LLC, a 10% owner, executed 18 separate sales totaling 727,793 shares for $51,634,252.32 across three trading dates (June 22–24, 2026) at blended average price of $70.95. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled rather than discretionary. While the non-derivative holding reaches 0 shares post-transaction, the insider retains substantial derivative holdings across 12 ownership vehicles totaling 26,497,370 shares of Class B Common Stock, so the overall position remains material. The stock currently trades at $70.56, near its 52-week high of $72.39, and has risen 27.7% over 30 days and 75.6% over 90 days. HNGE shows strong fundamentals with revenue of $182,307,000.00 and net income of $35,128,000.00 in the latest quarter, alongside annual revenue growth of +50.6%, though the company was unprofitable over its most recent full fiscal year.

James Pursley sells 33,000 HNGE shares for $2.3M via scheduled 10b5-1 plan; stock +27.4% in 30d

James Pursley, President of Hinge Health, executed 3 separate sales totaling 33,000 shares for $2,287,251.28 at a blended average price of $69.31 on 2026-06-22. This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-06-13, making it scheduled rather than discretionary. Post-transaction, Pursley retains 740,897 shares, representing a 4.3% reduction from his pre-transaction holdings of 773,897 shares. The stock has risen 27.4% over the prior 30 days and 75.1% over the prior 90 days, while his prior sells across all tickers (measured post-sale price movements) averaged +2.1% return at 30 days and +27.7% at 90 days. At the same ticker, his 2 most recent measurable prior sales (2026-03-23) produced 30-day returns of +4.7% and +8.6%, followed by 90-day returns of +62.4% and +68.4%. The company reported latest-quarter revenue of $182,307,000.00 and net income of $35,128,000.00, with annual revenue growth of +50.6%, though full-year net income was negative. This structured sale occurs against a backdrop of strong recent stock appreciation and mixed fundamental signals.

Insight Holdings Group (10% owner) sells 65,581 shares at $70.36 via 4 scheduled transactions totaling $4.6M

Insight Holdings Group executed 4 separate sales totaling 65,581 shares for $4,614,252.93 at $70.36 on 2026-06-16, eliminating non-derivative holdings under a pre-arranged 10b5-1 trading plan. The company reported strong fundamentals with revenue of $182,307,000.00 and net income of $35,128,000.00 in the latest quarter, plus annual revenue growth of +50.6%, yet was unprofitable over its most recent full fiscal year. The sale occurred near the 52-week high ($70.72), with the stock at $69.42 currently. The insider's prior sales at HNGE on 2025-12-01 showed 30d returns of -2.7% and 90d returns of -10.5%, while an earlier 2025-05-23 sale posted 90d gains of +75.0%, indicating inconsistent timing outcomes at this ticker. As a scheduled trade under 10b5-1 rules, this represents pre-planned capital allocation rather than discretionary market timing.

Director Gabriel M.I. Mecklenburg sold 50,000 shares at $65.53–$66.00 under 10b5-1 plan; retains 1,727,341 derivative shares

Director Gabriel M.I. Mecklenburg executed 2 sales totaling 50,000 shares for $3,276,843.09 on 2026-06-05 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-01. This represents a scheduled transaction, not a discretionary decision. The insider retains 1,727,341 Class B Common Stock shares as derivative holdings, so the non-derivative portion was reduced to zero while his overall position remains substantial. His 5 prior HNGE trades (all on 2026-06-01) showed 30-day and 90-day returns ranging from +3.4% to +13.0%, establishing a pattern of selling ahead of near-term appreciation at this ticker. The current price of $63.62 stands at -1.1% from the 52-week high of $64.30, and the stock has posted a 30-day change of +16.0% and a 90-day change of +37.9%, contextualizing the trade within a strong recent momentum period.

Director Gabriel Mecklenburg sells 83,334 shares ($5.0M) in 7 tranches at HNGE under scheduled 10b5-1 plan; retains 1,777,341 derivative shares.

Gabriel M.I. Mecklenburg, a Director at Hinge Health, executed 7 separate sales totaling 83,334 shares for $5,018,132.67 on 2026-06-01 at prices ranging from $55.74 to $61.68, with a blended average of $60.22. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning it is scheduled rather than discretionary. While the non-derivative holdings reached zero post-transaction, Mecklenburg retains 1,777,341 Class B Common Stock shares in derivative holdings, representing a substantial continued stake in the company. The 30-day and 90-day price appreciation of +20.0% and +28.0% respectively provides context on recent stock momentum, though his prior sales at HNGE have shown mixed near-term outcomes (ranging from -13.4% to +22.4% over 30 days). Hinge Health reported strong fundamentals with annual revenue growth of +50.6% and net income of $35.1M in the latest quarter, though the company was unprofitable over its most recent full fiscal year, warranting continued monitoring of profitability trajectory.